David Miller

A former biotech analyst, David has 20+ years of experience with business strategy, communications, and business analysis focusing on technology and biotechnology industries. He led the investor relations and communications program at Angion (NASDAQ:ANGN), helping take the company public via a 2021 IPO. He held a variety of roles at Alpine Immune Sciences (NASDAQ:ALPN), helping taking the company public via a reverse merger in 2017.